

Prolight has entered the year with several important milestones that further strengthen the position of our groundbreaking, IP-protected ultra-sensitive point-of-care (POC) technology, Psyros™. Particularly encouraging is the progress in our ongoing funded collaboration with BRAINBox Solutions, where we have achieved highly positive results in an analytical evaluation of three biomarkers for Traumatic Brain Injury (TBI).

STRONG RESULTS IN THE TBI PROJECT WITH BRAINBOX SOLUTIONS

The evaluation demonstrates that Psyros can efficiently transfer and detect multiple biomarkers with high sensitivity. This confirms both the platform's broad clinical potential and its ability to be rapidly adapted to new market segments.

These strong results are fully aligned with Prolight's strategy to establish Psyros as an ultra-sensitive and portable POC platform across multiple clinical areas. TBI represents a large and rapidly growing global market segment, driven by increasing incidence, evolving clinical guidelines, and a clear need for rapid, high-sensitivity diagnostics. The ability to measure multiple biomarkers simultaneously has the potential to be of significant importance in clinical practice.

PROJECT FULLY FUNDED BY BRAINBOX

Following successful completion of the initial evaluation phase by Prolight, BRAINBox has approved the start of the next phase, in which all three biomarkers will be evaluated using a biobank of 260 patient samples provided by BRAINBox from an ongoing pivotal clinical study in the United States.

Full external funding from BRAINBox means that Prolight's cost base remains unchanged. As the troponin project has now progressed into manufacturing scale-up and instrument design freeze, Prolight's assay development team—who had already been preparing to transition onto additional biomarker development—has been able to take on the TBI biomarker work using existing resources. This allows parallel progress in both TBI biomarker evaluation and the final stages of Psyros instrument development, without impacting overall timelines.

STRENGTHENED COMMERCIAL POSITION AND PARTNER INTEREST

The collaboration with BRAINBox further strengthens our position in ongoing and future partner discussions. The results demonstrate that new biomarkers—including those from entirely different clinical areas—can be rapidly integrated onto the Psyros platform. This makes the platform highly attractive to global diagnostics companies seeking POC solutions that combine low production costs, rapid turnaround times across multiple clinical applications, and multiplexing capability within one small blood test.

The initial contact with BRAINBox was established at the ADLM Congress in the United States, where we engaged with a number of potential partners. What particularly attracts both BRAINBox and other stakeholders is Psyros' ultra-sensitive POC platform, combined with very low cartridge manufacturing costs which is a significant competitive advantage in global high-volume markets.

THE ROLE OF THE TBI PROJECT IN PROLIGHT'S STRATEGY

By validating the capability of the Psyros platform beyond cardiac biomarkers, we strengthen our opportunities for future strategic collaborations across several major clinical areas, including sepsis and acute inflammation, autoimmune diseases, sexually transmitted infections, and other biomarker-driven segments.

Successful results from the upcoming biobank study of 260 patient samples are expected to further enhance Psyros' commercial value and strengthen our position ahead of the next phase of partner discussions across Europe, the United States, and Asia.

It is important to emphasize that the BRAINBox project runs fully in parallel with our core plan: to initiate the clinical performance study for high-sensitivity troponin in 2026 and to launch commercially in 2027. The study of the three TBI biomarkers will serve as a clear external validation of the Psyros platform's clinical potential and commercial relevance.

We look forward to continued progress throughout the year and thank you for your ongoing trust and support.

Ulf Bladin, CEO Prolight Diagnostics